3 July 2024
N4 Pharma
plc
("N4 Pharma" or the
"Company")
Nanogenics
Update
N4 Pharma Plc (AIM: N4P), the
specialist pharmaceutical company developing Nuvec®, a novel
delivery system for cancer treatments, gene therapy and vaccines,
is pleased to provide an update on its subsidiary, Nanogenics
Limited ("Nanogenics").
Nanogenics has now submitted an
application to the U.S. Food and Drug Administration ("FDA") to
obtain orphan drug designation for its product ECP105, for the
prevention of scarring following glaucoma surgery. Obtaining orphan
drug status in the USA is expected to bring substantial cost and
time savings on the development work and once approved, seven years
of exclusivity. A decision is expected by the FDA three months from
the date of application.
Alongside this, Nanogenics has also
filed a patent application in the UK for novel siRNA sequences that
can be used as part of the ECP105 development work.
Nigel Theobald, Chief Executive Officer of the Company,
commented:
"Having orphan drug status for ECP105 in the USA will be akin
to getting a patent granted as it provides exclusivity for the
treatment indication applied for.
"Alongside applying for orphan drug status in the USA,
Nanogenics is strengthening its IP position by filing a patent for
novel siRNA sequences which can be used to widen its product
protection further."
For
more information please contact:
|
N4
Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive
Director
Engage with us directly at N4 Pharma
Investor Hub
To hear more, visit
|
Via N4 Pharma Investor Hub
Sign up at investors.n4pharma.com
https://investors.n4pharma.com/link/WPGM9e
|
|
SP
Angel Corporate Finance
LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe/Kasia
Brzozowska (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob
Rees (Corporate Broking)
|
Tel: +44(0)20 3470 0470
|
|
Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
|
Tel: +44(0)20 3657 0050
|
|
|
|
About N4 Pharma
N4 Pharma is a specialist
pharmaceutical company developing a novel delivery system for
oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec® and Liptide, a unique
peptide/lipid delivery system via its subsidiary
Nanogenics.
N4 Pharma's business model is to
partner with companies developing products in these fields to use
Nuvec® or Liptide® as the delivery vehicle for these products. As
these products progress through pre‐clinical and clinical programs,
N4 Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the
market.
For further information on the Company
visit www.n4pharma.com or sign up at investors.n4pharma.com.
